Literature DB >> 2140517

The Zellweger syndrome: deficient conversion of docosahexaenoic acid (22:6(n-3)) to eicosapentaenoic acid (20:5(n-3)) and normal delta 4-desaturase activity in cultured skin fibroblasts.

M Grønn1, E Christensen, T A Hagve, B O Christophersen.   

Abstract

The metabolism of docosahexaenoic acid (22:6(n-3)) and adrenic acid (22:4(n-6)) was studied in cultured fibroblasts from patients with the Zellweger syndrome, X-linked adrenoleukodystrophy (X-ALD) and normal controls. It was shown that [4,5- 3H]22:6(n-3) is retroconverted to labelled eicosapentaenoic acid (20:5(n-3)) in normal and X-ALD fibroblasts, while this conversion is deficient in Zellweger fibroblasts. [U- 14C]Eicosapentaenoic acid (20:5(n-3)) is elongated to docosapentaenoic acid (22:5(n-3)) in all three cell lines. With [U- 14C]20:5(n-3) as the substrate, shorter fatty acids were not detected. With [4,5- 3H]22:6(n-3) as the substrate, labelled fatty acids were esterified in the phospholipid- and triacylglycerol-fraction to approximately the same extent in all three cell lines. [2- 14C]Adrenic acid (22:4(n-6)) was desaturated to 22:5(n-6) and elongated to 24:4(n-6) in all three cell lines and to the largest extent in the Zellweger fibroblasts. This agrees with the view that the delta 4-desaturase is not a peroxisomal enzyme. The observation that the retroconversion of 22:6(n-3) to 20:5(n-3) is deficient in Zellweger fibroblasts strongly suggest that the beta-oxidation step in the retroconversion is a peroxisomal function. Peroxisomal very-long-chain (lignoceroyl) CoA ligase is probably not required for the activation of 22:6(n-3), since the retroconversion to 20:5(n-3) is normal in X-ALD fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140517     DOI: 10.1016/0005-2760(90)90310-t

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men.

Authors:  H M Vidgren; J J Agren; U Schwab; T Rissanen; O Hänninen; M I Uusitupa
Journal:  Lipids       Date:  1997-07       Impact factor: 1.880

2.  Molecular species of phospholipids with very long chain fatty acids in skin fibroblasts of Zellweger syndrome.

Authors:  Kotaro Hama; Toru Nagai; Chiho Nishizawa; Kazutaka Ikeda; Masashi Morita; Noriko Satoh; Hiroki Nakanishi; Tsuneo Imanaka; Nobuyuki Shimozawa; Ryo Taguchi; Keizo Inoue; Kazuaki Yokoyama
Journal:  Lipids       Date:  2013-12       Impact factor: 1.880

Review 3.  On the molecular etiology of decreased arachidonic (20:4n-6), docosapentaenoic (22:5n-6) and docosahexaenoic (22:6n-3) acids in Zellweger syndrome and other peroxisomal disorders.

Authors:  J P Infante; V A Huszagh
Journal:  Mol Cell Biochem       Date:  1997-03       Impact factor: 3.396

4.  Chronic administration of eicosapentaenoic acid and docosahexaenoic acid as ethyl esters reduced plasma cholesterol and changed the fatty acid composition in rat blood and organs.

Authors:  L Frøyland; H Vaagenes; D K Asiedu; A Garras; O Lie; R K Berge
Journal:  Lipids       Date:  1996-02       Impact factor: 1.880

5.  Metabolic fate of docosahexaenoic acid (DHA; 22:6n-3) in human cells: direct retroconversion of DHA to eicosapentaenoic acid (20:5n-3) dominates over elongation to tetracosahexaenoic acid (24:6n-3).

Authors:  Hui Gyu Park; Peter Lawrence; Matthew G Engel; Kumar Kothapalli; James Thomas Brenna
Journal:  FEBS Lett       Date:  2016-09-02       Impact factor: 4.124

6.  N-3 and n-6 fatty acid metabolism in undifferentiated and differentiated human intestine cell line (Caco-2).

Authors:  Y S Huang; J W Liu; K Koba; S N Anderson
Journal:  Mol Cell Biochem       Date:  1995-10-18       Impact factor: 3.396

7.  Retroconversion is a minor contributor to increases in eicosapentaenoic acid following docosahexaenoic acid feeding as determined by compound specific isotope analysis in rat liver.

Authors:  Adam H Metherel; Raphaël Chouinard-Watkins; Marc-Olivier Trépanier; R J Scott Lacombe; Richard P Bazinet
Journal:  Nutr Metab (Lond)       Date:  2017-11-28       Impact factor: 4.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.